Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy

Caleb K Stein, Erin W Meermeier, Yuliza Shotts, Yuan Xiao Zhu, Chang-Xin Shi, Kirsten Pfeffer, Megan Du, Meaghen Sharik, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2024-212331

Published: 2024

Journal Articles

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Blood (2024) 144 (Supplement 1): 671.

https://doi.org/10.1182/blood-2024-202224

Published: 2024

Journal Articles

Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Erin W Meermeier, Caleb K Stein, Meaghen Sharik, Megan Du, Yuan Xiao Zhu, Chang-Xin Shi, Yuliza Shotts, Maria Josic, Keith Abayasiriwardana, Natalie Bezman, Timothy Fisher, Kristin Bompiani-Myers, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 358.

https://doi.org/10.1182/blood-2024-210917

Published: 2024

Journal Articles

Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN + Preclinical Model of Multiple Myeloma

Erin W Meermeier, Meaghen Sharik, Megan Du, Caleb K Stein, Yuan Xiao Zhu, Chang-Xin Shi, Yuliza Shotts, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 356.

https://doi.org/10.1182/blood-2024-212225

Published: 2024

Journal Articles

UnSETtling energy dependence of t(4;14) MM

P. Leif Bergsagel, Marta Chesi

Blood (2024) 144 (3): 244–245.

https://doi.org/10.1182/blood.2024024871

Published: 2024

Journal Articles

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Sinto Sebastian Chirackal, Taro Hitosugi, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2023-189785

Published: 2023

Journal Articles

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Laura Lucia Cogrossi, Matteo Grioni, Paola Zordan, Benedetta Mattorre, Marco Lorenzoni, Greta Meregalli, Anna Policastro, Roberto Ferrarese, Nicola Clementi, Sofia Sisti, Nicasio Mancini, Marta Chesi, P. Leif Bergsagel, Matteo Bellone

Blood (2023) 142 (Supplement 1): 754.

https://doi.org/10.1182/blood-2023-180145

Published: 2023

Journal Articles

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

Lorenzo Lindo, Erin Meermeier, Lauren H Wilkinson, Silvia Selleri, Mehdi Arbabi Ghahroudi, Scott McComb, P. Leif Bergsagel, Marta Chesi, Laura Evgin, Daniel D Waller, Kevin A Hay

Blood (2023) 142 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2023-178821

Published: 2023

Journal Articles

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Yan Cheng, Fumou Sun, Wancheng Guo, Hongwei Xu, Prasanth Viswanathan, Mark Manzano, Eric Siegel, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Marta Chesi, P. Leif Bergsagel, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3309.

https://doi.org/10.1182/blood-2023-187001

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Journal Articles

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Rodrigo Fonseca, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi, Akhilesh Pandey, Kiran Mangalaparthi, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, Bing Dai, Esteban Braggio, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7129–7130.

https://doi.org/10.1182/blood-2022-167372

Published: 2022

Journal Articles

Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma

Caleb K Stein, Erin Meermeier, Seth J Welsh, Marta Chesi, P. Leif Bergsagel

Blood (2022) 140 (Supplement 1): 7082–7083.

https://doi.org/10.1182/blood-2022-171104

Published: 2022

Journal Articles

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model

Erin Meermeier, Caleb K Stein, Meaghen E Sharik, Yuan Xiao Zhu, Megan T Du, Seth J Welsh, Chang-Xin Shi, Matthew L Wheeler, P. Leif Bergsagel, Marta Chesi

Blood (2022) 140 (Supplement 1): 7056–7057.

https://doi.org/10.1182/blood-2022-167668

Published: 2022

Journal Articles

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Yuan Xiao Zhu, Gregory J Ahmann, Laura Ann Bruins, Mariano Arribas, Xianfeng Chen, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca, Lisa M. Rimsza

Blood (2022) 140 (Supplement 1): 4187–4188.

https://doi.org/10.1182/blood-2022-157316

Published: 2022

Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio

Blood (2022) 140 (Supplement 1): 4135–4136.

https://doi.org/10.1182/blood-2022-170944

Published: 2022

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Francesco Maura, David Coffey, Esteban Braggio, Caleb K Stein, Meaghen E Sharik, Megan T Du, Bachisio Ziccheddu, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, Marta Chesi

Blood (2022) 140 (Supplement 1): 1540–1541.

https://doi.org/10.1182/blood-2022-166614

Published: 2022

Journal Articles

Prolonged Maintenance of Ex Vivo Functional Vk*MYC Multiple Myeloma Cells Allows for in Vitro Manipulation and Subsequent In Vivo Analysis

Frances E Lock, Afsaneh Panahi, Ariene Cabantog, Lorenzo Lindo, Daniel Waller, Kevin Hay, Marta Chesi, Arefeh Rouhi, Florian Kuchenbauer

Blood (2022) 140 (Supplement 1): 12448–12449.

https://doi.org/10.1182/blood-2022-162860

Published: 2022

Journal Articles

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Yao Yao, Woojun D Park, Eugenio Morelli, Mehmet K. Samur, Nicholas P Kwiatkowski, Ryosuke Shirasaki, Yan Xu, Chandraditya Chakraborty, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Constantine S. Mitsiades, Lin Charles, Nikhil C. Munshi, Mariateresa Fulciniti

Blood (2021) 138 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2021-153469

Published: 2021

NARROW

Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN + Preclinical Model of Multiple Myeloma

UnSETtling energy dependence of t(4;14) MM

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Prolonged Maintenance of Ex Vivo Functional Vk*MYC Multiple Myeloma Cells Allows for in Vitro Manipulation and Subsequent In Vivo Analysis

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only